Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.
Abstract Number: 5538
Abstract Type : Poster Session
Indication : mCRPC
Intervention : Olaparib
Company : AstraZeneca and Merck Sharp & Dohme Corp
Technology : Small Molecule
85% and 76% of olaparib pts were free of pain progression (worst pain item) compared with 75% and 51% in the pcNHA arm, respectively at 6 and 12 months. The proportion of pts without pain progression (overall pain severity) also favoured olaparib (Table). Median time to first opiate use was significantly prolonged in olaparib arm compared with pcNHA arm; 18 months for olaparib vs 9 months for pcNHA (Table). BPI-SF pain interference scores were also more favourable for olaparib than pcNHA; difference in overall adjusted mean change from baseline score 20.75 (95% CI: 21.14, 20.36) P=0.0002. Further pain burden results for cohort A will also be presented.
Olaparib reduced the burden of pain and time to first opiate use in pts with mCRPC and HRR gene alterations vs pcNHA, demonstrating a clinical and symptomatic patient benefit.
The reduced burden of pain observed with olaparib over the control treatment was manifested by a statistically significant delay in time to pain progression and a trend toward a delay in the overall population